Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

NCT06582017 is registered in ClinicalTrials.gov with Nammi Therapeutics Inc as lead sponsor.

NCT NCT06582017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06582017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Lead sponsor
Nammi Therapeutics Inc
Phase
Phase 1
Overall status
Recruiting
Start date
August 28, 2024
Completion date
May 30, 2028
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, pancreas cancer, prostate cancer, renal cell carcinoma, urothelial carcinoma